Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelics Industry News Stories for the Week of June 22nd – 28th, 2020.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view full article.
The newly awarded cannabis licenses will allow Red White & Bloom (CSE: RWB) (OTCQX: TDRYD) investee PharmaCo to expand its cultivation capacity in Michigan. The harvest will provide the Michigan market with a much-needed supply of ultra-premium, lab-approved cannabis amid the current statewide product shortage.
When asked about the possibility of a recreational Psychedelic market, here’s what some of the biggest names in the industry had to say. Their answers may surprise some.
The number of banks and credit unions servicing marijuana businesses dipped in the last fiscal quarter, according to new federal data.
MindMed (NEO: MMED) (OTCQB: MMEDF) (FRA: BGHM) announced the company is developing technologies and analytics that seek to personalize psychedelic therapy experiences for a specific patient. The technology aims to optimize the dosing of MDMA, LSD and other psychedelics based on a patient’s profile.
In 2018, Emblem Cannabis signed a deal in which Aphria (TSX: APHA) (NYSE: APHA) (FRA: 10E) would provide 175,000 kilograms (38,580 pounds) of cannabis over five years, beginning in May 2019. Aleafia Health (TSX: ALEF) (OTCQX: ALEAF) (FRA: ARAH) cancelled the agreement in August 2019, saying Aphria had failed to meet its supply obligations.
The successful use of controlled substances such as Ketamine and Psilocybin mushrooms to treat mental health issues like depression and anxiety has ushered in a new era of interest in Psychedelic drugs. But for researchers and clinicians eager to expand such therapies, an obvious question remains: Does treatment with psychedelics necessarily require a psychedelic experience?
MindMed (NEO: MMED) (OTCQB: MMEDF) (FRA: BGHM) the leading neuro-pharmaceutical company for psychedelic inspired medicines is rapidly advancing its drug development pipeline and R&D activities since its listing on March 3, 2020.
Three members of Congress took to the House floor on Thursday to argue that marijuana reform should not be set aside and forgotten as the body approves policing overhaul legislation.
After years of circling the industry looking for signs to invest, and while watching the growing need for opioid-free mental health treatment, investors are now beginning to see Psychedelics as a sure thing.
Could an economic recession, a pandemic, and widespread social unrest actually spell opportunity for the legal marijuana industry in the USA?